J Cancer 2020; 11(21):6454-6459. doi:10.7150/jca.48691 This issue
1. 3rd University General Hospital, “AHEPA” University Hospital, Thessaloniki, Greece.
2. Department of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, Thessaloniki, Greece.
3. Thoracic Surgery Department, “Interbalkan” European Medical Center, Thessaloniki, Greece.
4. Oncology Department, “Interbalkan” European Medical Center, Thessaloniki, Greece.
5. Oncology Department, (NHS) Genaral Hospital of Kavala, Kavala, Greece.
6. Sana Clinic Group Franken, Department of Cardiology/Pulmonology/Intensive Care/Nephrology, “Hof” Clinics, University of Erlangen, Hof, Germany.
7. Department of Pulmonology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich Switzerland.
8. Department of Respiratory Medicine, Changhai Hospital of Second Military Medical University, Shanghai, China.
9. Scientigraphy Department, “Bioclinic” Private Laboratory, Thessaloniki, Greece.
10. Second Department of Surgery, General University Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
11. Oncology Department, General Hospital of Volos, Volos, Greece.
12. Department of Pulmonology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
13. Faculty of Medicine, University of Novi Sad, Institute for Pulmonary Diseases of Vojvodina, Novi Sad, Serbia.
14. Radiology Department, Democritus University of Thrace, Alexandroupolis, Greece.
15. Private Pathology Laboratory, “Microdiagnostics”, Thessaloniki, Greece.
16. Radiology Department, “Euromedica” Private Radiology Laboratory, Thessaloniki, Greece.
17. Oncology Department, “Bioclinic” Private Hospital, Thessaloniki, Greece.
18. Internal Medicine Department, University of Ioannina, Ioannina, Greece.
Introduction: Novel technologies are currently used for lung cancer diagnosis. EBUS-TBNA 22G is considered one of the most important tools. However; there are still issues with the sample size.Patients and Methods: 223 patients underwent EBUS-TBNA with a 21G Olympus needle, 22GUS Mediglobe and 22GUB Mediglobe. In order to evaluate the efficiency of 22GUB novel needle design. In order to evaluate the sample size of each needle, we constructed cell blocks and measured the different number of slices from each biopsy site.
Results: The 22GUB novel needle had similar and larger number of slices from each biopsy site compared to 21G needle.
Discussion: Firstly as a novel methodology we used the number of slices from the constructed cell blocks in order to evaluate the sample size. Secondly, we should seek novel needle designs and not only concentrate on the volume of the sample size.
Keywords: Mediglobe, Olympus, EBUS, lung cancer, bronchoscopy, cell blocks, lymphnodes, NSCLC